### Tetrahedron Letters 72 (2021) 153056

Contents lists available at ScienceDirect

**Tetrahedron Letters** 

journal homepage: www.elsevier.com/locate/tetlet

# Re-visiting the diastereoselectivity of organocatalytic conjugate addition of 2-trimethylsiloxyfuran to *trans*-crotonaldehyde



# Liubo Li, Anton El Khoury, Brennan O. Clement, Patrick G. Harran\*

Department of Chemistry and Biochemistry, University of California-Los Angeles, 607 Charles E. Young Drive East, Los Angeles, CA 90095-1569, United States

#### ARTICLE INFO

Article history: Received 18 February 2021 Revised 25 March 2021 Accepted 30 March 2021 Available online 6 April 2021

Keywords: Mukaiyama-Michael reaction Butenolide

#### ABSTRACT

We describe the re-assignment of configuration previously ascribed to product diastereomers resultant from imidazolidinone-catalyzed conjugate addition of 2-trimethylsiloxyfuran to *trans*-crotonaldehyde. A modified procedure that uses a diphenylprolinol catalyst was subsequently developed to selectively provide the 'syn' diastereomeric product in high enantiomeric excess on decagram scales.

© 2021 Elsevier Ltd. All rights reserved.

The catalyzed conjugate addition of 2-siloxyfurans to Michael acceptors is a valuable method to prepare  $\gamma$ -substituted butenolides – a structural motif commonly observed in natural products and synthetic drug substances [1]. Studies by Brown and co-workers [2] demonstrated that chiral imidazolidinones could catalyze asymmetric conjugate addition of siloxyfurans to enal acceptors. Following that report, additional organocatalysts were shown effective for the transformation [3]. As part of studies aimed at synthesizing the pro-apoptotic natural product portimine [4], we required scalable access to the (3*S*, 5*R*) enantiomer of butenolide 1, a 'syn' diastereomer resultant from adding 2(5*H*)-furanone (or 2-trimethylsiloxyfuran) to *trans*-crotonaldehyde (Fig. 1A).

Of the known syntheses of **1** [3a-c], only Brown and co-workers reported [2] isolating the molecule in high diastereomeric and enantiomeric excess. In our hands, however, imidazolidinone catalyzed addition of 2-trimethylsiloxyfuran to *trans*-crotonaldehyde gave two isomeric butenolides in a ratio of ~2:1. Moreover, data originally reported for those products were inconsistent with that expected when using *trans*-crotonaldehyde. Instead, it appeared to reflect products derived from using 4-methyl-2-pentenal in the reaction [9]. Adding to this puzzle was the fact that <sup>1</sup>H NMR data for isomers **1** prepared by others were conflicting (Fig. 1B) [3a-c]. Lastly, related reactions of 2(5*H*)-furanone derivatives with (*E*)- $\beta$ methyl Michael acceptors gave mainly *anti* diastereomers [3a,5] or were non-selective [3b,3c]. For our own studies to progress, we needed to clarify these findings and develop an efficient, selective and scalable synthesis of (3*S*, 5*R*)-**1**. We synthesized racemic **1** using a procedure developed by Yadav and co-workers for the addition of 2-trimethylsiloxyfuran to enones [6]. Stirring 2-trimethylsiloxyfuran with crotonaldehyde in the presence of catalytic  $I_2$  gave (±)-**1** with exquisite stereocontrol (76%, dr > 20:1). When that material was reduced under Luche conditions and the incipient alcohol treated with NaH (THF, rt), one isomer of bicyclic tetrahydropyran **3** was isolated, albeit in low yield. *J*-couplings and NOE data (see ESI for details) obtained for **3** supported the stereochemistry drawn in Scheme **1**, thereby implying precursor (±)-**1** was 'anti' (as drawn). Further support for this assignment came from hydrogenating (±)-**1**, oxidizing the product under Pinnick conditions and coupling the resultant acid with 2-oxazolidone to afford imide (±)-**4**. NMR spectral data for (±)-**4** were identical to those reported by Katsuki [5a].

Having identified the *anti* diastereoisomer of **1**, we confirmed the identity of the *syn* diastereomer through regioselective Wacker–Tsuji oxidation [7] of (3*S*, 5*S*)- $\gamma$ -butyrolactone **5** [8] to afford aldehyde **6**. The <sup>1</sup>H NMR spectrum of **6** was identical to that obtained by hydrogenating the minor isomer of **1** obtained from the Brown catalysis (Table 1, entry 1). Thus, the 2:1 mixture of isomers generated using the Brown procedure favors the *anti*-diastereomer, not the *syn* as reported. Our assignments are in agreement with those made by Yanai and co-workers [3a] and contrary to those made by Luo and co-workers. The major diastereomer isolated by Luo is *syn*, not *anti* as reported [3b].

Confident in our relative stereochemical assignments, we next sought to optimize the catalytic asymmetric synthesis of (3S, 5R)-1. We screened diastereoselectivity in the addition of 2-trimethylsiloxyfuran to *trans*-crotonaldehyde using several



<sup>\*</sup> Corresponding author. E-mail address: harran@chem.ucla.edu (P.G. Harran).



**Fig. 1. A**) Butenolide **1** maps cleanly onto a segment of portimine. **B**) Data for isomers **1** synthesized by organocatalytic methods were missing and, in part, conflicting; <sup>a</sup>as originally assigned; <sup>b</sup>not reported.



**Scheme 1.** Syntheses of *syn* and *anti* **1** by non-organocatalyzed means.<sup>a</sup> Reagents and conditions: (a) *trans*-crotonaldehyde (0.7 eq.), l<sub>2</sub> (7 mol%), Et<sub>2</sub>O (0.07 M), -78 °C, 76%, *dr* > 20:1; (b) CeCl<sub>3</sub>·7H<sub>2</sub>O (2.0 eq.), NaBH<sub>4</sub> (2.0 eq.), MeOH (0.05 M), 0 °C, 60%; (c) NaH (2.0 eq.), THF (0.05 M), rt, 25%; (d) Pd(OH)<sub>2</sub>/C (3 mol%), H<sub>2</sub> (balloon), MeOH (0.3 M), rt; (e) NaClO<sub>2</sub> (5.0 eq.), NaH<sub>2</sub>PO<sub>4</sub> (6.0 eq.), *tBuOH*: amylene:H<sub>2</sub>O (1.5:1:1, 0.05 M), rt; (f) EDCI·HCl (1.4 eq.), oxazolidinone (1.3 eq.), DMAP (1.15 eq.), CH<sub>2</sub>Cl<sub>2</sub> (0.1 M), rt; 20% from (±)-*anti*-1; (g) Pd(PhCN)<sub>2</sub>Cl<sub>2</sub> (7.5 mol %), *tBuOH* (0.05 M), rt, 51% brsm.



<sup>a</sup> Reagents and conditions: **2** (1.0 eq.), crotonaldehyde (3.0 eq.), cat. (20 mol%), acid (20 mol%),  $H_2O$  (2.0 eq.), solvent (0.1 M), -10 °C.

<sup>b</sup> dr measured by <sup>1</sup>H NMR.

 $^c\,$  DCA: dichloroacetic acid, reaction was performed with 5.0 eq. of  $H_2O$  in 0.5 M of CHCl3 at -78  $^oC.$ 

DNBA: 2,4-dinitrobenzoic acid.

 $^{\rm e}\,$  Parallel reactions were carried out at -10 °C and 50 °C. Both resulted in similar selectivity.

f (3*R*, 5*S*)-**1** was the major product.

<sup>g</sup> crotonaldehyde (5.0 eq.), H<sub>2</sub>O (3.0 eq.)

<sup>h</sup> The reaction was left at -20 °C overnight after 1 h at -10 °C.

<sup>i</sup> 10 mol% of **9** and 13 mol% of TFA was used.

 $^{j}$  TFA (26 mol%), **2** was added over 7 h at -15 °C, *er* > 20:1, measured on a chiral amine derivative by <sup>1</sup>H NMR.

organocatalysts under varied conditions (see Table 1). Imidazolidinone catalyst **7** [2] in the presence of co-catalytic protic acids uniformly gave poor diastereoselectivities, although the major isomer did switch from *anti* to *syn* when TFA in THF was used (Entry 4).

A set of hydroxyproline-derived catalysts **8a-c** were then synthesized and their performance were examined. Under the conditions shown in Table 1, each formed *syn*-1 as the major diastereomer, although selectivities were modest (Entries 5–9). Improvements came when simpler diphenylprolinol catalyst **9** was employed. At  $-20 \,^{\circ}$ C in THF, 20 mol% **9** and TFA catalyzed formation of *syn* and *anti* **1** in a 5:1 ratio (Entry 10). Selectivity was not diminished when the catalyst loading was reduced to 10 mol% (Entry 11). When siloxyfuran **2** was added slowly (7 h) to a stirred THF solution of crotonaldehyde containing catalyst **9** and TFA at  $-15 \,^{\circ}$ C, diastereoselectivity increased to 8.5:1 (Entry 12) [9].

This last procedure could be scaled to support our total synthesis studies (Scheme 2). On 0.15 mol scale (0.1 M in THF), the reaction was stirred at -15 °C for 1 h after the addition of **2** was complete. The reaction was filtered through a pad of silica gel and concentrated. The crude material was dissolved in MeOH and hydrogenated over Pd(OH)<sub>2</sub>/C to give  $\gamma$ -butyrolactone **6** (12.9 g, 54%, *dr* = 8.5:1) following chromatography. Isolated **6** showed  $[\alpha]_{D}^{23} = +30.8 (c = 0.1, CHCl_3)$  and material synthesized previously from alkene **5** (Scheme 1) gave  $[\alpha]_{D}^{24} = +26.7 (c = 0.1, CHCl_3), confirming absolute stereochemistry as (35, 55). An enan-$ 



**Scheme 2.** Scalable asymmetric synthesis of butyrolactone **6**.<sup>a</sup> <sup>a</sup>Reagents and conditions: (a) 2 (1.0 eq.), crotonaldehyde (5.0 eq.), cat. (20 mol%), acid (26 mol%), H<sub>2</sub>O (3.0 eq.), THF (0.1 M), -15 °C; (b) Pd(OH)<sub>2</sub>/C (3 mol%), H<sub>2</sub> (balloon), MeOH (0.3 M), rt; 54% over 2 steps.

tiomeric ratio of >20:1 in 6 was inferred from <sup>1</sup>H NMR analysis of the diastereomeric products derived from reductive amination with (S)- $\alpha$ -methylbenzylamine (see ESI).

In summary, we have firmly assigned relative stereochemistry to diastereomeric products derived from conjugate addition of 2-trimethylsiloxyfuran to trans-crotonaldehyde. We have developed an iodine catalyzed version of the reaction that provides the racemic *anti* diastereomer with high selectivity (dr > 20:1). The optically active syn diastereomer is produced selectively on scale using a diphenylprolinol catalyst. Attempts to elaborate (+)-**6** to portimine are ongoing and will be reported shortly.

#### **Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

Funding provided by the D. J. & J. M. Cram Endowment, the George Gregory Fellowship (fellowship to LL) and NSF equipment grant CHE1048804.

# Appendix A. Supplementary data

Experimental procedures and spectral data can be found in ESI. Supplementary data to this article can be found online at https://doi.org/10.1016/j.tetlet.2021.153056.

#### References

- [1] (a) Y.S. Rao, Chem. Rev. 64 (1964) 353;
  - (b) R.R. Kitson, A. Millemaggi, R.J. Taylor, Angew. Chem. Int. Ed. 48 (2009) 9426; (c) G. Casiraghi, L. Battistini, C. Curti, G. Rassu, F. Zanardi, Chem. Rev. 111 (2011) 3076
  - (d) X. Jusseau, L. Chabaud, C. Guillou, Tetrahedron 70 (2014) 2595;
- (e) B. Mao, M. Fananas-Mastral, B.L. Feringa, Chem. Rev. 117 (2017) 10502. [2] S.P. Brown, N.C. Goodwin, D.W. MacMillan, J. Am. Chem. Soc. 125 (2003)
- 1192 [3] (a) H. Yanai, A. Takahashi, T. Taguchi, Chem. Commun. 46 (2010) 8728;
- (b) X. Luo, Z. Zhou, F. Yu, X. Li, X. Liang, J. Ye, Chem. Lett. 40 (2011) 518:

(c) EK Kemppainen G Sahoo A Piisola A Hamza B Kotai I Papai PM Pihko Chem. Eur. J. 20 (2014) 5983;

- (d) X. Li, M. Lu, Y. Dong, W. Wu, O. Qian, J. Ye, D.J. Dixon, Nat. Commun. 5 (2014) 4479.
- (e) A. Quintard, A. Lefranc, A. Alexakis, Org. Lett. 13 (2011) 1540;
- (f) J. Wang, C. Qi, Z. Ge, T. Cheng, R. Li, Chem. Commun. 46 (2010) 2124; (g) Y. Zhang, C. Yu, Y. Ji, W. Wang, Chem. Asian J. 5 (2010) 1303;
- (h) H. Huang, F. Yu, Z. Jin, W. Li, W. Wu, X. Liang, J. Ye, Chem. Commun. 46 (2010) 5957
- (i) M. Terada, K. Ando, Org. Lett. 13 (2011) 2026;
- (j) M.S. Manna, V. Kumar, S. Mukherjee, Chem. Commun. 48 (2012) 5193;
- (k) A.K. Simlandy, S. Mukherjee, Org. Biomol. Chem. 14 (2016) 5659;
- (1) Z.H. Wang, Z.J. Wu, X.Q. Huang, D.F. Yue, Y. You, X.Y. Xu, X.M. Zhang, W.C. Yuan, Chem. Commun. 51 (2015) 15835;
- (m) U. Das, Y.R. Chen, Y.L. Tsai, W. Lin, Chem. Eur. J. 19 (2013) 7713;
- (n) W. Zhang, D. Tan, R. Lee, G. Tong, W. Chen, B. Qi, K.W. Huang, C.H. Tan, Z. Jiang, Angew. Chem. Int. Ed. 51 (2012) 10069;
- (o) Y.-L. Guo, L.-N. Jia, L. Peng, L.-W. Qi, J. Zhou, F. Tian, X.-Y. Xu, L.-X. Wang, RSC Advances (2013) 3:
- (p) E.K. Kemppainen, G. Sahoo, A. Valkonen, P.M. Pihko, Org. Lett. 14 (2012) 1086
- [4] A.I. Selwood, A.L. Wilkins, R. Munday, F. Shi, L.L. Rhodes, P.T. Holland, Tetrahedron Lett. 54 (2013) 4705.
- (a) H. Kitajima, K. Ito, T. Katsuki, Tetrahedron 53 (1997) 17015; [5] (b) G. Desimoni, G. Faita, S. Filippone, M. Mella, M.G. Zampori, M. Zema, Tetrahedron 57 (2001) 10203; (c) S. Kim, H. Yang, Synlett 2008 (2008) 555.
- [6]
- J.S. Yadav, B.V.S. Reddy, G. Narasimhulu, N.S. Reddy, P.J. Reddy, Tetrahedron Lett. 50 (2009) 3760.
- [7 X.S. Ning, M.M. Wang, C.Z. Yao, X.M. Chen, Y.B. Kang, Org. Lett. 18 (2016) 2700.
- L.M. Suen, M.L. Steigerwald, J.L. Leighton, Chem. Sci. 4 (2013) 2413. [8]
- [9] Under the conditions shown in Table 1 entry 12, the reaction of 2trimethylsiloxyfuran and 4-methyl-2-pentenal gave a 6:1 mixture of diastereomeric butenolides. The <sup>1</sup>H NMR spectrum of the major isomeric product (syn-10) corresponded to the major isomer reported by Luo (ref. 3b), whereas the <sup>1</sup>H NMR spectrum of the minor isomeric product (anti-10) matched the data reported for syn-1 in ref 2

